Project ORCA – First Antibody Antagonist to a Physiocrine Immunology Pathway
Based on our knowledge of Physiocrine biology, we have established a third biologics program from our research efforts, project ORCA, currently in preclinical development. Project ORCA represents a third therapeutic modality distinct from Resolaris or iMod.Fc.
ORCA targets a novel, proprietary immuno-oncology pathway using antibodies to change levels of Resokine in multiple tumor settings. We believe tumors utilize Resokine to evade immune system responses.
The company plans to identify an IND candidate from project ORCA in 2017.